Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2004

View Archived Issues

Bifunctional drug inhibits beta-amyloid aggregation in vitro

Treatment with LXR agonist T-0901317 affects APP processing, ABCA1 upregulation and Abeta secretion

New data on mild cognitive impairment and its relationship with Alzheimer's disease

Dual TNF-alpha and COX-2 inhibitor for the treatment of inflammatory diseases

Antitumor colchicine derivatives prepared at Aventis

Novel HDAC inhibitors in early development at Roche

Ecgonine and ecgonidine analogues and their use reported by Entropin

New oxazolidinones with antiviral activity identified at Bayer

Novel MCH antagonists and their use in obesity and related disorders

New monoamine reuptake inhibitors discovered by Lilly researchers

Acorda Therapeutics acquires Zanaflex rights from Elan

New South African phase II study for Hemopure in trauma patients

Celera Diagnostics and Merck & Co. enter Alzheimer's collaboration

GenVec and NIAID advance HIV vaccine into clinical testing

ISTA launches Istalol for glaucoma

Enrollment completed in phase II LymphoStat-B studies in RA and SLE

Gemzar combination therapy receives European approvals for ovarian cancer

Chromos Molecular Systems completes acquisition of CellExSys

Positive outcome of Dynavax phase IIa asthma challenge study

Forbes Medi-Tech adds cholesterol absorption inhibitors to pipeline

Preliminary 30-month data show benefit of Raptiva in psoriasis

Further positive phase I/II data for NX-1207 in BPH

Pramipexole and levodopa confer benefit to Parkinson's disease patients

NY-ESO-1/ISCOMATRIX cancer vaccine shows promise in clinical study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...